BioRestorative Therapies (BRTX) Company Overview

BioRestorative Therapies, Inc. (NASDAQ:BRTX ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Stephen Kilmer – Investor Relations Lance Alstodt – Chairman and Chief Executive Officer Francisco Silva – Vice President-Research and Development Conference Call Participants Jonathan Aschoff – ROTH Capital Michael Okunewitch – Maxim Group Elemer Piros – Rodman Operator Greetings. Welcome to the BioRestorative Third Quarter 2024 Results and New Additional Preliminary BRTX-100 Phase 2 Study Data Review Conference Call.

– Allows for the processing of allogeneic (non-autologous) donor tissue material, including stem cells, for medical research –

MELVILLE, N.Y., Oct. 03, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a regenerative medicine innovator focused on stem cell-based therapies and products, today announced that its Chief Executive Officer, Lance Alstodt, will participate in the 3rd Annual ROTH Healthcare Opportunities Conference on October 9, 2024 in New York City.

Biorestorative Therapies, Inc. (BRTX) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to loss of $0.77 per share a year ago.

- New journal section will focus on emerging and translation work in the field of regenerative medicine - MELVILLE, N.Y., July 23, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a clinical stage company focused on stem cell-based therapies, is pleased to announce that its Chief Scientist and Vice President of Research and Development, Francisco Silva, has been named Section Editor of the newly launched Regenerative Medicine section of the Journal of Translational Medicine.

– Adds to comprehensive patent portfolio underlying novel ThermoStem ® technology platform –

- Brown adipose derived stem cells with brown adipogenic potential would represent a new modality for the treatment of obesity and related metabolic disorders –

Biorestorative Therapies, Inc. (BRTX) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to loss of $1.53 per share a year ago.

MELVILLE, NY., June 04, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that CEO Lance Alstodt will participate at the Jefferies Global Healthcare Conference being held June 5-6, 2024 at the Marriot Marquis in New York. Management will also be available for one-on-one investor meetings during the conference.